- Home
- BCAB vs VSTM Comparison
BCAB vs VSTM Comparison
Compare BCAB & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- VSTM
- Stock Information
- Founded
- BCAB 2007
- VSTM 2010
- Country
- BCAB United States
- VSTM United States
- Employees
- BCAB N/A
- VSTM N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- VSTM Health Care
- Exchange
- BCAB Nasdaq
- VSTM Nasdaq
- Market Cap
- BCAB 96.2M
- VSTM 132.0M
- IPO Year
- BCAB 2020
- VSTM 2012
- Fundamental
- Price
- BCAB $2.08
- VSTM $3.97
- Analyst Decision
- BCAB Strong Buy
- VSTM Strong Buy
- Analyst Count
- BCAB 2
- VSTM 8
- Target Price
- BCAB $6.00
- VSTM $14.57
- AVG Volume (30 Days)
- BCAB 1.6M
- VSTM 1.1M
- Earning Date
- BCAB 11-08-2024
- VSTM 11-06-2024
- Dividend Yield
- BCAB N/A
- VSTM N/A
- EPS Growth
- BCAB N/A
- VSTM N/A
- EPS
- BCAB N/A
- VSTM N/A
- Revenue
- BCAB N/A
- VSTM $10,000,000.00
- Revenue This Year
- BCAB N/A
- VSTM N/A
- Revenue Next Year
- BCAB N/A
- VSTM $125.69
- P/E Ratio
- BCAB N/A
- VSTM N/A
- Revenue Growth
- BCAB N/A
- VSTM N/A
- 52 Week Low
- BCAB $1.14
- VSTM $2.10
- 52 Week High
- BCAB $4.02
- VSTM $14.22
- Technical
- Relative Strength Index (RSI)
- BCAB 55.80
- VSTM 63.77
- Support Level
- BCAB $1.87
- VSTM $3.11
- Resistance Level
- BCAB $2.13
- VSTM $3.76
- Average True Range (ATR)
- BCAB 0.12
- VSTM 0.33
- MACD
- BCAB 0.00
- VSTM 0.04
- Stochastic Oscillator
- BCAB 68.90
- VSTM 94.26
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.